RDiscovery invests into Sanodyne Therapeutics

Jun 5, 2025 — RDiscovery has made an investment in Sanodyne Therapeutics, Inc. (headquartered in Chuo-ku, Tokyo, Japan; Representative Director Kazuhiko Nonomura, Ph.D.).
Sanodyne Therapeutics is dedicated to creating innovative therapies based on its proprietary small-molecule compound, SNT-001, which has the potential to be a disease-modifying drug in peripheral neuropathy and neuropathic pain.
RDiscovery supports Sanodyne’s technology and business development through its participation in the Board of Directors meetings and other activities to increase the value of the lead program, an innovation originating in Japan.
https://sanodyne.com/en/

about company
At Sanodyne Therapeutics, we are dedicated to bringing hope and relief to patients suffering from peripheral neuropathy and neuropathic pain.
We are committed to developing innovative therapies that restore comfort and improve quality of life. By leveraging cutting-edge science and our deep experience in pain management.